ibrutinib + rituximab + vincristine + ifosfamide + carboplatin + idarubicin + dexamethasone

This is a **combination regimen** made up of seven active pharmaceutical ingredients: ibrutinib, rituximab, vincristine, ifosfamide, carboplatin, idarubicin, and dexamethasone. Each drug has a distinct mechanism of action targeting malignant B cells and other cancer cells by disrupting cell signaling (ibrutinib as a Bruton’s tyrosine kinase inhibitor), mediating immune attack (rituximab as an anti-CD20 monoclonal antibody), inhibiting microtubule formation (vincristine), causing DNA crosslinking and alkylation (ifosfamide, carboplatin), inhibiting topoisomerase II (idarubicin), and exerting anti-inflammatory and lympholytic effects (dexamethasone as a corticosteroid). This intensive regimen is investigational for treatment of aggressive B-cell malignancies, most likely in clinical trials studying approaches for relapsed or refractory lymphomas or leukemias, especially when high-risk features or resistance to standard treatments are present.